Cargando…
Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors
INTRODUCTION: The discovery of activating KIT and PDGFRα mutations in gastrointestinal stromal tumors (GISTs) represented a milestone as it allowed clinicians to use tyrosine kinase inhibitors, like imatinib, to treat this sarcoma. Although surgery remains the only potentially curative treatment, pa...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824223/ https://www.ncbi.nlm.nih.gov/pubmed/23775094 http://dx.doi.org/10.1007/s11605-013-2243-0 |